Pro-gastrin-releasing peptide(31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase

We attempted to clarify whether serum levels of a carboxy-terminal fragment of ProGRP, ProGRP(31-98), could serve as a more accurate tumour marker in patients with SCLC than neuron-specific enolase (NSE). ProGRP(31-98) and NSE were measured retrospectively in 101 newly diagnosed untreated patients w...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of cancer Vol. 73; no. 10; pp. 1227 - 1232
Main Authors:	TAKADA, M, KUSUNOKI, Y, KIKUI, N, MORINO, H, FUKUOKA, M, MASUDA, N, MATUI, K, YANA, T, USHIJIMA, S, IIDA, K, TAMURA, K, KOMIYA, T, KAWASE, I
Format:	Journal Article
Language:	English
Published:	Basingstoke Nature Publishing Group 01-05-1996
Subjects:	Biological and medical sciences Biomarkers, Tumor Carcinoma, Small Cell - diagnosis Carcinoma, Small Cell - metabolism Carcinoma, Small Cell - pathology Carcinoma, Small Cell - therapy Female Gastrin-Releasing Peptide Gastrins - metabolism Humans Lung Neoplasms - diagnosis Lung Neoplasms - metabolism Lung Neoplasms - pathology Lung Neoplasms - therapy Male Medical sciences Neoplasm Metastasis Peptides - metabolism Phosphopyruvate Hydratase - metabolism Pneumology Protein Precursors - metabolism Tumors of the respiratory system and mediastinum Human Lung disease Respiratory disease Enzyme Isozyme Peptide hormone Lyases Tumoral marker Malignant tumor Neuropeptide Bronchopulmonary Gastrin releasing peptide Sensitivity Gastrointestinal hormone Bronchus disease Serum Biosynthesis precursor Diagnosis Oat cell carcinoma Carbon-oxygen lyases Comparative study Phosphopyruvate hydratase Hydro-lyases
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We attempted to clarify whether serum levels of a carboxy-terminal fragment of ProGRP, ProGRP(31-98), could serve as a more accurate tumour marker in patients with SCLC than neuron-specific enolase (NSE). ProGRP(31-98) and NSE were measured retrospectively in 101 newly diagnosed untreated patients with SCLC, 111 with non-small-cell lung cancer (NSCLC) and 114 patients with non-malignant lung diseases. ProGRP(31-98) and NSE levels were determined using a sandwich enzyme-linked immunosorbent assay. Sensitivity in SCLC patients was 72.3% for ProGRP(31-98) and 62.4% for NSE. Comparing the area under curve (AUC) of 'receiver operator characteristics' of ProGRP(31-98) with that of NSE, ProGRP(31-98) was the more powerful marker in the diagnosis of SCLC (P = 0.0001). Serum levels of ProGRP(31-98) were higher in the 40 patients with extensive disease than in the 61 patients with limited disease (P = 0.0082). ProGRP(31-98) was significantly higher in patients with pure small-cell carcinoma than in patients with mixed small-cell/large-cell carcinoma (P = 0.02). In serial measurement in 16 patients responding to treatment, a high degree of correlation was noted between the decrease in serum ProGRP(31-98) levels and clinical response during the second week after treatment (P = 0.0045). These results indicate that the determination of serum ProGRP(31-98) levels plays an important role in the diagnosis and treatment of SCLC patients.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0007-0920 1532-1827
DOI:	10.1038/bjc.1996.235